UC
MCID: ULC004
MIFTS: 80

Ulcerative Colitis (UC)

Categories: Blood diseases, Gastrointestinal diseases

Aliases & Classifications for Ulcerative Colitis

MalaCards integrated aliases for Ulcerative Colitis:

Name: Ulcerative Colitis 39 12 77 26 38 44 15 17 74 3
Inflammatory Bowel Disease, Ulcerative Colitis Type 26
Chronic Left-Sided Ulcerative Colitis 74
Left-Sided Ulcerative Colitis 12
Left Sided Ulcerative Colitis 74
Idiopathic Proctocolitis 26
Colitis, Ulcerative 45
Colitis Ulcerative 56
Colitis Gravis 26
Uc 26

Classifications:



External Ids:

Disease Ontology 12 DOID:8577
KEGG 38 H01466
ICD9CM 36 556 556.5 556.9
MeSH 45 D003093
NCIt 51 C2952
ICD10 34 K51 K51.9

Summaries for Ulcerative Colitis

MedlinePlus : 44 Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Ulcerative Colitis, also known as inflammatory bowel disease, ulcerative colitis type, is related to pyoderma gangrenosum and colonic disease, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Ulcerative Colitis is IFNG-AS1 (IFNG Antisense RNA 1), and among its related pathways/superpathways are Cytokine-cytokine receptor interaction and JAK-STAT signaling pathway. The drugs Benzocaine and tannic acid have been mentioned in the context of this disorder. Affiliated tissues include Bone, colon and testes, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A colitis that is predominantly confined to the mucosa located in colon and includes characteristic ulcers, or open sores.

Genetics Home Reference : 26 Ulcerative colitis is a chronic disorder that affects the digestive system. This condition is characterized by abnormal inflammation of the inner surface of the rectum and colon, which make up most of the length of the large intestine. The inflammation usually causes open sores (ulcers) to develop in the large intestine. Ulcerative colitis usually appears between ages 15 and 30, although it can develop at any age. The inflammation tends to flare up multiple times throughout life, which causes recurring signs and symptoms.

CDC : 3 Inflammatory Bowel Disease (IBD) is a broad term that describes conditions characterized by chronic inflammation of the gastrointestinal tract. The two most common inflammatory bowel diseases are ulcerative colitis and Crohn’s disease. Inflammation affects the entire digestive tract in Crohn’s disease and only the large intestine (also called the colon) in ulcerative colitis. Both illnesses involved an abnormal response to the body’s immune system.

Wikipedia : 77 Ulcerative colitis (UC) is a long-term condition that results in inflammation and ulcers of the colon... more...

Related Diseases for Ulcerative Colitis

Diseases related to Ulcerative Colitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 848)
# Related Disease Score Top Affiliating Genes
1 pyoderma gangrenosum 33.0 CXCL8 NOD2 TNF
2 colonic disease 33.0 MLH1 MSH2 NOD2
3 pouchitis 32.8 CXCL8 IL10 NOD2 TLR4
4 inflammatory bowel disease 31.8 ABCB1 ATG16L1 CRP CXCL8 IL10 IL1B
5 pyoderma 31.7 CXCL8 NOD2 TNF
6 cytomegalovirus infection 31.5 CXCL8 IL1B TNF
7 colitis 31.4 ABCB1 ATG16L1 CXCL8 IL10 IL1B IL2
8 crohn's disease 31.4 ABCB1 ATG16L1 CRP IL10 IL23R IRGM
9 crohn's colitis 31.4 CXCL8 IL1B IL2 NOD2 TNF
10 ileitis 31.3 MPO NOD2 TLR4 TNF
11 proctitis 31.1 CRP MPO TNF
12 bronchiolitis obliterans 31.0 CXCL8 IL10 TNF
13 arthritis 30.9 CXCL8 IL10 IL1B NOD2 TNF
14 uveitis 30.8 IL10 NOD2 TNF
15 myasthenia gravis 30.8 IL10 IL2 TNF
16 spondylitis 30.7 CRP IL23R NOD2 TNF
17 ileocolitis 30.7 MYO9B NOD2 TNF
18 spondyloarthropathy 1 30.6 CRP NOD2 TLR4 TNF
19 osteomyelitis 30.6 CXCL8 IL10 IL1B TNF
20 interstitial lung disease 30.6 CXCL8 IL10 IL1B TNF
21 pericarditis 30.6 CRP IL1B TNF
22 inflammatory bowel disease 5 30.6 ATG16L1 IL23R NOD2
23 bronchiolitis 30.5 CRP CXCL8 IL10 TLR4 TNF
24 lung disease 30.5 CXCL8 IL10 IL1B MPO TNF
25 autoimmune disease 30.5 IL10 IL1B IL2 TNF
26 acute pancreatitis 30.4 CRP CXCL8 IL10 MPO
27 endomyocardial fibrosis 30.4 IL10 TNF
28 aspergillosis 30.4 IL10 TLR4 TNF
29 hematopoietic stem cell transplantation 30.4 IL10 IL2 TNF
30 autoimmune inner ear disease 30.4 MPO TNF
31 peptic ulcer disease 30.4 CXCL8 IL10 IL1B TNF
32 obstructive jaundice 30.3 CRP CXCL8 TNF
33 colorectal adenocarcinoma 30.3 MLH1 MSH2 MUC2
34 human immunodeficiency virus infectious disease 30.3 IL10 IL2 TNF
35 familial mediterranean fever 30.3 CRP IL1B NOD2 TNF
36 extrinsic allergic alveolitis 30.3 CXCL8 IL10 IL1B MPO
37 pneumonia 30.3 CRP CXCL8 IL10 IL1B MPO TLR4
38 duodenal ulcer 30.3 CXCL8 IL1B TNF
39 meningitis 30.3 CRP CXCL8 IL10 IL1B TNF
40 endocarditis 30.2 CRP CXCL8 IL10 TNF
41 appendicitis 30.2 CRP CXCL8 IL10 IL1B MPO TNF
42 spondylarthropathy 30.2 NOD2 TLR4 TNF
43 sarcoidosis 1 30.2 IL1B IL2 NOD2 TNF
44 wells syndrome 30.2 CRP CXCL8 IL1B IL2
45 transverse myelitis 30.1 CXCL8 IL10 TNF
46 eales disease 30.1 IL10 IL1B TNF
47 tonsillitis 30.1 CXCL8 IL1B IL2 TNF
48 psoriatic arthritis 30.1 CRP IL1B IL23R NOD2 TNF
49 chronic fatigue syndrome 30.1 IL10 IL1B IL2 TNF
50 acquired immunodeficiency syndrome 30.1 IL10 IL1B IL2 TNF

Comorbidity relations with Ulcerative Colitis via Phenotypic Disease Network (PDN): (show all 11)


Active Peptic Ulcer Disease Acute Cystitis
Crohn's Disease Deficiency Anemia
Esophagitis Hypothyroidism
Inflammatory Bowel Disease 1 Intestinal Obstruction
Iron Deficiency Anemia Paralytic Ileus
Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Ulcerative Colitis:



Diseases related to Ulcerative Colitis

Symptoms & Phenotypes for Ulcerative Colitis

UMLS symptoms related to Ulcerative Colitis:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

GenomeRNAi Phenotypes related to Ulcerative Colitis according to GeneCards Suite gene sharing:

27 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.88 CXCL8 IL10 IL1B IL2 MLH1 MPO
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.88 CXCL8 IL10 IL1B IL2 MLH1 MPO
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-111 9.73 NOD2
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.73 CRP
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.73 IL10
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.73 IL10
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.73 CRP
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.73 IL10
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 9.73 IL10
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.73 CRP IL10 NOD2 TLR4
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 9.73 CRP

MGI Mouse Phenotypes related to Ulcerative Colitis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.1 ABCB1 ATG16L1 IL10 IL1B IL2 IL23R
2 cardiovascular system MP:0005385 10.07 ABCB1 ATG16L1 CRP IL10 IL1B IL2
3 digestive/alimentary MP:0005381 10.06 ABCB1 ATG16L1 IL10 IL2 IL23R MLH1
4 homeostasis/metabolism MP:0005376 10 ABCB1 ATG16L1 CRP IL10 IL1B IL2
5 immune system MP:0005387 9.83 ABCB1 ATG16L1 CRP IL10 IL1B IL2
6 neoplasm MP:0002006 9.28 IL10 IL1B IL2 IL23R MLH1 MSH2

Drugs & Therapeutics for Ulcerative Colitis

Drugs for Ulcerative Colitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 357)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
2
tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 1401-55-4
3
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 50-03-3
4
Hydrocortisone Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 50-23-7 5754
5
Azathioprine Approved Phase 4,Phase 3,Phase 2,Not Applicable 446-86-6 2265
6
Adalimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 331731-18-1 16219006
7
Iron Approved, Experimental Phase 4,Phase 3,Phase 2 7439-89-6, 15438-31-0 23925 27284
8
Infliximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 170277-31-3
9
leucovorin Approved Phase 4,Phase 2,Not Applicable 58-05-9 6006 143
10
Tocopherol Approved, Investigational Phase 4,Phase 2,Not Applicable 1406-66-2 14986
11
Zinc Approved, Investigational Phase 4,Not Applicable 7440-66-6 32051
12
Copper Approved, Investigational Phase 4 7440-50-8 27099
13 Vedolizumab Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 943609-66-3
14
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 83-43-2 6741
15
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 2921-57-5
16
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 302-25-0
17
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-24-8 5755
18
Aminosalicylic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 65-49-6 4649
19
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 93-14-1 3516
20
Ciprofloxacin Approved, Investigational Phase 4,Not Applicable 85721-33-1 2764
21
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
22
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
23
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492 6473866
24
Mercaptopurine Approved Phase 4,Phase 3,Phase 2,Not Applicable 50-44-2 667490
25
Linaclotide Approved Phase 4 851199-59-2 65351
26
Amoxicillin Approved, Vet_approved Phase 4,Not Applicable 26787-78-0 33613
27
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 564-25-0 54671203
28
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
29
Metronidazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 443-48-1 4173
30
Tofacitinib Approved, Investigational Phase 4,Phase 3,Phase 1 477600-75-2
31
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 73590-58-6 4594
32
carbamide peroxide Approved Phase 4 124-43-6
33
Methotrexate Approved Phase 4,Phase 2,Not Applicable 1959-05-2, 59-05-2 126941
34
Vancomycin Approved Phase 4,Phase 2,Phase 1,Not Applicable 1404-90-6 441141 14969
35
Certolizumab pegol Approved Phase 4,Phase 2 428863-50-7
36
Ustekinumab Approved, Investigational Phase 4,Phase 3 815610-63-0
37
Sodium Citrate Approved, Investigational Phase 4,Not Applicable 68-04-2
38
Magnesium citrate Approved Phase 4 3344-18-1
39
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
40
Losartan Approved Phase 4 114798-26-4 3961
41
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
42
Caffeine Approved Phase 4 58-08-2 2519
43
Dextromethorphan Approved Phase 4 125-71-3 5362449 5360696
44
Thioguanine Approved Phase 4 154-42-7 2723601
45
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
46
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Not Applicable 59-02-9 14985
47
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 59-30-3 6037
48
Vitamin C Approved, Nutraceutical Phase 4,Not Applicable 50-81-7 5785 54670067
49
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7440-70-2 271
50
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 77-92-9 311

Interventional clinical trials:

(show top 50) (show all 1057)
# Name Status NCT ID Phase Drugs
1 Efficacy of Treatment With Berberine to Maintain Remission in Ulcerative Colitis Unknown status NCT02962245 Phase 4 berberine;regular treatment
2 Physiological Intermolecular Modification Spectroscopy (PIMS) in Ulcerative Colitis With Golimumab Unknown status NCT02186886 Phase 4 Golimumab
3 Role of Healthy Bacteria in Ulcerative Colitis Unknown status NCT01479660 Phase 4 Probiotic
4 Mesalazine With Hydrocortisone Sodium Succinate Enema for 4-Week Treatment in Patients With Ulcerative Colitis Unknown status NCT03110198 Phase 4 Mesalazine;hydrocortisone sodium succinate;Mesalazine with hydrocortisone sodium succinate
5 Fecal Microbiota Transplantation for Ulcerative Colitis Through Colonic Transendoscopic Enteral Tubing Unknown status NCT02998112 Phase 4 fecal microbiota transplantation;Saline
6 Golimumab in Steroid-dependent Ulcerative Colitis: Induction and Maintenance of Clinical and Endoscopic Remission Unknown status NCT02412085 Phase 4 Golimumab
7 Azathioprine Based on Endoscopy After Clinical Remission in Moderate to Severe Ulcerative Colitis Unknown status NCT02579733 Phase 4 Azathioprine;Placebo
8 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation, Endothelial Function, and Markers of Inflammation Unknown status NCT01078935 Phase 4
9 Brief Escalation of Adalimumab Treatment for Prevention of Clinical Relapse in IBD Unknown status NCT03059849 Phase 4 Adalimumab
10 Anemia in Inflammatory Bowel Disease Unknown status NCT02760940 Phase 4 oral liposomal iron
11 "Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial" Unknown status NCT02452151 Phase 4 Infliximab-Biosimilar;Infliximab-Innovator
12 Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab Unknown status NCT02453776 Phase 4 PRECISION dosing Infliximab
13 The Effect of Probiotics on Exacerbation of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) Unknown status NCT01765998 Phase 4 Probiotic;Placebo
14 Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With IBD Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
15 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease Unknown status NCT01632462 Phase 4 VSL#3
16 Manipulation of Visceral Sensitivity and Immune System in IBS Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
17 Pain Relief In Irritable Bowel Syndrome Unknown status NCT02573844 Phase 4 Proklama
18 Treatment of Ulcerative Colitis With Ciprofloxacin and E. Coli Nissle Completed NCT01772615 Phase 4 Ciprofloxacin
19 Evaluation of Histologic and Endoscopic Remission Induced by Infliximab in Moderate to Severe Ulcerative Colitis Completed NCT01408810 Phase 4 Infliximab
20 Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032) Completed NCT02092285 Phase 4 Golimumab
21 Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC) Completed NCT00446849 Phase 4 MMX Mesalamine
22 Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027) Completed NCT02155335 Phase 4 Prefilled Syringe delivery of Golimumab;Smartject Device delivery of Golimumab
23 Once Versus Twice Daily Mesalamine to Induce Remission in Pediatric Ulcerative Colitis Completed NCT01201122 Phase 4 Mesalamine
24 Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis Completed NCT00542152 Phase 4 CYCLOSPORINE VS INFLIXIMAB
25 Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis Completed NCT01124149 Phase 4 MMX mesalamine/ mesalazine
26 Asacol Dosing Study for Active Ulcerative Colitis Completed NCT00194818 Phase 4 Asacol (mesalamine)
27 Adacolumn in Refractory UC Patients Trial Completed NCT01481142 Phase 4
28 Dose Escalation and Remission (DEAR) Completed NCT00652145 Phase 4 mesalamine
29 Predicting Response to Standardized Pediatric Colitis Therapy Completed NCT01536535 Phase 4 Mesalamine;Corticosteroid;Corticosteroids then mesalamine
30 Study for the Treatment of Ulcerative Colitis With Adacolumn (Companion to US Study 512-04-205) Completed NCT00219414 Phase 4
31 Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease Completed NCT02559713 Phase 4 Vedolizumab
32 Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022). Completed NCT02318667 Phase 4
33 The NOR-SWITCH Study Completed NCT02148640 Phase 4 Innovator infliximab;Biosimilar infliximab
34 Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis Completed NCT01418131 Phase 4 Rectal tacrolimus;Placebo
35 Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD) Completed NCT01346826 Phase 4 Standard 2 hours-infusion;Accelerated 1 hour-infusion;Accelerated 30 minutes-infusion
36 Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate Completed NCT01991314 Phase 4 Ferrous sulphate
37 Immunogenicity of Hepatitis A Vaccine in Inflammatory Bowel Disease (IBD) Patients Completed NCT01341808 Phase 4
38 The Influence of 5–Aminosalicylates on Thiopurine Metabolite Levels Completed NCT00167882 Phase 4 5-aminosalicylate (Pentasa, Ferring)
39 Single-dose Linaclotide for Capsule Endoscopy Preparation Completed NCT02465385 Phase 4 Linaclotide
40 Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease Completed NCT01981889 Phase 4 Prednisone
41 Efficacy Study of Pneumococcal Vaccination in Crohn's Disease Completed NCT01505855 Phase 4 23-valent polysaccharide pneumococcal vaccine
42 Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing Completed NCT01174186 Phase 4 Adalimumab
43 Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease Completed NCT01034358 Phase 4
44 A Trial of Iron Replacement in Patients With Iron Deficiency. Completed NCT01067547 Phase 4 Iron Sucrose.;Iron sucrose
45 The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012) Completed NCT01668004 Phase 4
46 Induction of Immunity Against Streptococcus Pneumoniae in Adults With Inflammatory Bowel Disease Completed NCT01908283 Phase 4
47 Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis Recruiting NCT02345733 Phase 4 Antibiotic cocktail
48 A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission Recruiting NCT03281304 Phase 4 CP-690,500 5 mg;CP-690,550 10 mg
49 Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis Recruiting NCT02770040 Phase 4 Infliximab
50 Endovenous Corticosteroid Pulses in Moderate Ulcerative Colitis Recruiting NCT02921555 Phase 4 Methylprednisolone;Prednisone

Search NIH Clinical Center for Ulcerative Colitis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Ulcerative Colitis cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: colitis, ulcerative

Genetic Tests for Ulcerative Colitis

Anatomical Context for Ulcerative Colitis

MalaCards organs/tissues related to Ulcerative Colitis:

42
Colon, Testes, T Cells, Neutrophil, Bone, Monocytes, Skin

The Foundational Model of Anatomy Ontology organs/tissues related to Ulcerative Colitis:

20
Colon
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Ulcerative Colitis:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate

Publications for Ulcerative Colitis

Articles related to Ulcerative Colitis:

(show top 50) (show all 5971)
# Title Authors Year
1
Colorectal cancer and dysplasia risk in patients with ulcerative colitis at a tertiary referral center in Turkey. ( 30843860 )
2019
2
Whole Exome Sequencing of Ulcerative Colitis-associated Colorectal Cancer Based on Novel Somatic Mutations Identified in Chinese Patients. ( 30794281 )
2019
3
Surveillance Colonoscopy for Ulcerative Colitis-Associated Colorectal Cancer Offers Better Overall Survival in Real-World Surgically Resected Cases. ( 30747769 )
2019
4
Loss of RUNX3 Immunoreactivity in Non-Neoplastic Rectal Mucosa May Predict the Occurrence of Ulcerative Colitis-Associated Colorectal Cancer. ( 30763934 )
2019
5
Oral Vancomycin Induces and Maintains Remission of Ulcerative Colitis in the Subset of Patients With Associated Primary Sclerosing Cholangitis. ( 30838381 )
2019
6
Enterotoxigenic Clostridium perfringens Infection as an Adverse Event After Faecal Microbiota Transplantation in Two Patients With Ulcerative Colitis and Recurrent Clostridium difficile Infection: A Neglected Agent in Donor Screening. ( 30852608 )
2019
7
Emu Oil reduces disease severity in a mouse model of chronic ulcerative colitis. ( 30907169 )
2019
8
A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review. ( 30908297 )
2019
9
Off-label prescriptions of drugs used for the treatment of Crohn's disease or ulcerative colitis. ( 30908719 )
2019
10
The Synergistic Role of Diet and Exercise in the Prevention, Pathogenesis, and Management of Ulcerative Colitis: An Underlying Metabolic Mechanism. ( 30911221 )
2019
11
DUBLIN (Degree of Ulcerative colitis Burden of Luminal INflammation) score, a simple method to quantify inflammatory burden in Ulcerative Colitis. ( 30911757 )
2019
12
Structural weakening of the colonic mucus barrier is an early event in ulcerative colitis pathogenesis. ( 30914450 )
2019
13
MiR-146a regulates the development of ulcerative colitis via mediating the TLR4/MyD88/NF-κB signaling pathway. ( 30915760 )
2019
14
Inhibition of tumor necrosis factor alpha and increased of interleukin 10 by Lactobacillus: a molecular mechanism protection against TNBS-induced ulcerative colitis in chicks. ( 30821556 )
2019
15
Association between dietary iron and zinc intake and development of ulcerative colitis: A case-control study in Japan. ( 30821862 )
2019
16
Risk factors and timing for colectomy in chronically active refractory ulcerative colitis: A systematic review. ( 30826279 )
2019
17
Nivolumab-induced immune-mediated colitis: an ulcerative colitis look-alike-report of new cases and review of the literature. ( 30826963 )
2019
18
Ulcerative Colitis: Shifting Sands. ( 30827006 )
2019
19
High-Dose Infliximab Rescue Therapy for Hospitalized Acute Severe Ulcerative Colitis. ( 30830524 )
2019
20
Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis. ( 30830573 )
2019
21
Not your typical inflammatory bowel disease flare: diarrhea and weight loss masquerading as recrudescence of ulcerative colitis. ( 30831082 )
2019
22
Two-year delay in ulcerative colitis diagnosis is associated with anti-tumor necrosis factor alpha use. ( 30833804 )
2019
23
A comprehensive review and update on ulcerative colitis. ( 30837080 )
2019
24
Presence of pseudopolyps in ulcerative colitis is associated with a higher risk for treatment escalation. ( 30837789 )
2019
25
Unusual Manifestation of Ulcerative Colitis. ( 30838150 )
2019
26
ACG Clinical Guideline: Ulcerative Colitis in Adults. ( 30840605 )
2019
27
CTGF-mediated ERK signaling pathway influences the inflammatory factors and intestinal flora in ulcerative colitis. ( 30841458 )
2019
28
Gut mucosal virome alterations in ulcerative colitis. ( 30842211 )
2019
29
Pretreatment neutrophil-to-lymphocyte ratio predicts clinical relapse of ulcerative colitis after tacrolimus induction. ( 30845259 )
2019
30
Early dose optimization of golimumab in nonresponders to induction treatment for ulcerative colitis is effective and supported by pharmacokinetic data. ( 30847474 )
2019
31
Clinical decision support improves quality of care in patients with ulcerative colitis. ( 30847962 )
2019
32
Best practices on immunomodulators and biological agents for Ulcerative colitis and Crohn's disease in Asia. ( 30848854 )
2019
33
FMT for ulcerative colitis: closer to the turning point. ( 30850823 )
2019
34
Ulcerative colitis associated with gastric heterotopia in the rectum: a case report. ( 30851180 )
2019
35
Surgery During Admission for an Ulcerative Colitis Flare: Should Pouch Formation Be Considered? ( 30852448 )
2019
36
Patients Who Undergo Colectomy for Pediatric Ulcerative Colitis at Low-volume Hospitals Have More Complications. ( 30853617 )
2019
37
Comparative effectiveness of antitumour necrosis factor agents and vedolizumab in ulcerative colitis. ( 30855421 )
2019
38
Aberrant alteration of follicular T helper cells in ulcerative colitis patients and its correlations with interleukin-21 and B cell subsets. ( 30855475 )
2019
39
A Macromolecular Janus Kinase (JAK) Inhibitor Prodrug Effectively Ameliorates Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice. ( 30859327 )
2019
40
Clostridium difficile Enteritis after Total Abdominal Colectomy for Ulcerative Colitis. ( 30863646 )
2019
41
Novel Leucocyte/Thrombocyte Apheresis for Induction of Steroid-Free Remission in Ulcerative Colitis: A Controlled Randomized Pilot Study. ( 30863856 )
2019
42
Vitamin D deficiency in adult patients with ulcerative colitis: Prevalence and relationship with disease severity, extent, and duration. ( 30864011 )
2019
43
Over-Expression of Immunosuppressive Molecules, PD-L1 and PD-L2, in Ulcerative Colitis Patients. ( 30864556 )
2019
44
Investigation on Spectrum-Effect Correlation between Constituents Absorbed into Blood and Bioactivities of Baizhu Shaoyao San before and after Processing on Ulcerative Colitis Rats by UHPLC/Q-TOF-MS/MS Coupled with Gray Correlation Analysis. ( 30866532 )
2019
45
Protective effect of TSLP and IL-33 cytokines in ulcerative colitis. ( 30868311 )
2019
46
The effects of two vitamin D regimens on ulcerative colitis activity index, quality of life and oxidant/anti-oxidant status. ( 30871542 )
2019
47
Role of Fecal Microbiota Transplantation for Maintenance of Remission in Patients with Ulcerative Colitis: A Pilot Study. ( 30873549 )
2019
48
Anti-commensal IgG Drives Intestinal Inflammation and Type 17 Immunity in Ulcerative Colitis. ( 30876876 )
2019
49
The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis. ( 30879034 )
2019
50
Distinct patterns of naïve, activated and memory T and B cells in blood of patients with ulcerative colitis or Crohn's disease. ( 30883691 )
2019

Variations for Ulcerative Colitis

Expression for Ulcerative Colitis

LifeMap Discovery
Genes differentially expressed in tissues of Ulcerative Colitis patients vs. healthy controls: 35 (show all 12)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CLDN8 claudin 8 Colon - 4.72 0.000
2 LCN2 lipocalin 2 Colon + 4.60 0.000
3 REG3A regenerating islet-derived 3 alpha Colon + 4.41 0.001
4 SLC26A2 solute carrier family 26 (anion exchanger), member 2 Colon - 4.19 0.000
5 PCK1 phosphoenolpyruvate carboxykinase 1 (soluble) Colon - 4.13 0.000
6 CXCL8 chemokine (C-X-C motif) ligand 8 Colon + 3.86 0.003
7 CXCL2 chemokine (C-X-C motif) ligand 2 Colon + 3.85 0.000
8 REG1A regenerating islet-derived 1 alpha Colon + 3.68 0.005
9 RGS3 regulator of G-protein signaling 3 Colon + 3.58 0.000
10 CXCL1 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) Colon + 3.55 0.000
11 OLFM4 olfactomedin 4 Colon + 3.25 0.014
12 DEFA6 defensin, alpha 6, Paneth cell-specific Colon + 3.22 0.003
Search GEO for disease gene expression data for Ulcerative Colitis.

Pathways for Ulcerative Colitis

Pathways related to Ulcerative Colitis according to KEGG:

38
# Name Kegg Source Accession
1 Cytokine-cytokine receptor interaction hsa04060
2 JAK-STAT signaling pathway hsa04630
3 Inflammatory bowel disease (IBD) hsa05321

Pathways related to Ulcerative Colitis according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 CRP CXCL8 IL10 IL1B IL2 IL23R
2
Show member pathways
13.35 CXCL8 IL10 IL1B IL2 IL23R NOD2
3
Show member pathways
13.3 CXCL8 IL10 IL1B IL2 IL23R MYO9B
4
Show member pathways
13.12 ATG16L1 CXCL8 IL10 IL1B IL2 NOD2
5
Show member pathways
12.87 ABCB1 CXCL8 IL10 IL1B IL2 TNF
6 12.83 CXCL8 IL2 IL23R MLH1 MSH2
7
Show member pathways
12.57 CXCL8 IL1B IL2 TLR4 TNF
8 12.56 IL10 IL1B IL2 MPO TNF
9
Show member pathways
12.49 IL10 IL1B IL2 IL23R NOD2 TLR4
10
Show member pathways
12.45 IL10 IL1B IL2 IL23R MPO MSH2
11
Show member pathways
12.41 IL10 IL1B IL2 TNF
12
Show member pathways
12.34 CRP IL1B IL2 MPO TNF
13
Show member pathways
12.3 CXCL8 IL1B TLR4 TNF
14
Show member pathways
12.26 CXCL8 IL10 IL1B IL2 TNF
15
Show member pathways
12.26 IL10 IL1B IRGM TLR4 TNF
16
Show member pathways
12.23 CXCL8 IL1B MUC2 TNF
17
Show member pathways
12.22 IL10 IL1B IL2 TNF
18 12.21 IL10 IL1B NOD2 TLR4 TNF
19
Show member pathways
12.19 CXCL8 IL1B TLR4 TNF
20 12.19 MLH1 MSH2 TLR4